Literature DB >> 2610506

Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with renal insufficiency.

J Kneer1, Y K Tam, R A Blouin, F J Frey, E Keller, C Stathakis, B Luginbuehl, K Stoeckel.   

Abstract

The pharmacokinetics of cefetamet after a short intravenous infusion of cefetamet (515 mg) and oral administration of 1,000 mg of cefetamet pivoxil were studied in 9 healthy subjects and in 38 patients with various degrees of renal impairment. The results showed that cefetamet elimination was dependent on renal function. After intravenous dosing, total body (CLS), renal (CLR), and nonrenal (CLNR) clearances were linearly related to creatinine clearance (CLCR; r = 0.95, 0.92, and 0.59, respectively). Elimination half-life (t1/2 beta) was prolonged from 2.46 +/- 0.33 h in normal subjects to 29.1 +/- 13.9 h in patients with CLCR of less than 10 ml/min per 1.73 m2. Correspondingly, CLS and CLR decreased from 1.77 +/- 0.27 and 1.42 +/- 0.25 ml/min per kg to 0.14 +/- 0.04 and 0.04 +/- 0.03 ml/min per kg, respectively. The volume of distribution at steady state (0.298 +/- 0.049 liter/kg) for cefetamet was not altered by renal insufficiency (P greater than 0.05). After oral administration, the elimination parameters, t1/2 beta and CLR, were insignificantly different from the intravenous data (P greater than 0.05). Furthermore, the bioavailability (F) of cefetamet pivoxil (45 +/- 13%) was not altered by renal failure (P greater than 0.05). However, maximum concentration in plasma and the time to achieve this value were significantly increased (5.86 +/- 0.74 versus 14.8 +/- 6.14 micrograms/ml and 3.9 +/- 1.1 versus 8.4 +/- 1.7 h, respectively; P less than 0.05). Based on these observations, it is recommended that patients with CLcr of <10 ml/min per 1.73 m2 and between 10 and 39 ml/min per 1.73 m2 be given one-quarter of the normal daily dose either once or twice daily. Patients with CLcr between 40 and 80 ml/min per 1.73 m2 should receive one-half of the normal dose twice daily. For patients with CLcr of <10 ml/min per 1.73 m2, it would be recommended that they receive a normal standard dose as a loading dose on day 1 of treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2610506      PMCID: PMC172794          DOI: 10.1128/AAC.33.11.1952

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Pharmacokinetics of intravenous cefetamet (Ro 15-8074) and oral cefetamet pivoxil (Ro 15-8075) in young and elderly subjects.

Authors:  R A Blouin; J Kneer; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  [Direct estimation of creatinine in serum and in urine without deproteinization using a modified Jaffé method].

Authors:  R Helger; H Rindfrey; J Hilgenfeldt
Journal:  Z Klin Chem Klin Biochem       Date:  1974-07

3.  Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency.

Authors:  R Verbeeck; T B Tjandramaga; A Mullie; R Verbesselt; R Verberckmoes; P J de Schepper
Journal:  Br J Clin Pharmacol       Date:  1979-03       Impact factor: 4.335

4.  Pharmacokinetics of cefetamet (Ro 15-8074) and cefetamet pivoxil (Ro 15-8075) after intravenous and oral doses in humans.

Authors:  J R Koup; U C Dubach; R Brandt; R Wyss; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

5.  Steady-state serum levels of quinidine and active metabolites in cardiac patients with varying degrees of renal function.

Authors:  D E Drayer; D T Lowenthal; K M Restivo; A Schwartz; C E Cook; M M Reidenberg
Journal:  Clin Pharmacol Ther       Date:  1978-07       Impact factor: 6.875

6.  Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics.

Authors:  A U Gerber; H P Brugger; C Feller; T Stritzko; B Stalder
Journal:  J Infect Dis       Date:  1986-01       Impact factor: 5.226

7.  Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.

Authors:  D R Guay; R C Meatherall; G K Harding; G R Brown
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

8.  Kinetics of procainamide and N-acetylprocainamide in renal failure.

Authors:  T P Gibson; A J Atkinson; E Matusik; L D Nelson; W A Briggs
Journal:  Kidney Int       Date:  1977-12       Impact factor: 10.612

9.  Determination of cefetamet and its orally active ester, cefetamet pivoxyl, in biological fluids by high-performance liquid chromatography.

Authors:  R Wyss; F Bucheli
Journal:  J Chromatogr       Date:  1988-08-19

10.  Pharmacokinetics of carumonam in patients with renal insufficiency.

Authors:  F Horber; H J Egger; E Weidekamm; U C Dubach; F J Frey; P J Probst; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1986-01       Impact factor: 5.191

View more
  10 in total

1.  Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.

Authors:  J V St Peter; M T Borin; G S Hughes; J S Kelloway; B E Shapiro; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in children.

Authors:  W L Hayton; R A Walstad; E Thurmann-Nielsen; T Kufaas; J Kneer; R J Ambros; H E Rugstad; E Monn; E Bodd; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

Review 3.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.

Authors:  W L Hayton; J Kneer; R A Blouin; K Stoeckel
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  A General Biphasic Bodyweight Model for Scaling Basal Metabolic Rate, Glomerular Filtration Rate, and Drug Clearance from Birth to Adulthood.

Authors:  Teh-Min Hu
Journal:  AAPS J       Date:  2022-05-10       Impact factor: 3.603

Review 6.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

Review 8.  Cefetamet pivoxil clinical pharmacokinetics.

Authors:  R A Blouin; K Stoeckel
Journal:  Clin Pharmacokinet       Date:  1993-09       Impact factor: 6.447

9.  Pharmacokinetics and pharmacodynamics of oral and intravenous cefetamet in dog.

Authors:  Wei Wang; Xiao-Mao Zhu; Chun-Mei Wang; Si Gou; Zhong-Hua Chen; Yuan Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-13       Impact factor: 2.441

Review 10.  Future directions in antimicrobial chemotherapy.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1992-08-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.